Auto Amazon Links: No products found. Blocked by captcha.
The ongoing battle concerning the availability of the life-extending prostate cancer drug, abiraterone, through the NHS in England has raged on, with a cancer charity expressing their frustration and anger over the lack of approval from ministers and health officials. While the drug has been accessible in Scotland and Wales for high-risk patients for the past two years, it remains unavailable in England and Northern Ireland. In a communication addressed to Prostate Cancer UK, Health Minister Karin Smyth mentioned that the decision by NHS England, after an extensive review, was primarily influenced by overall affordability and that intervention would not be deemed appropriate.
For individuals in England and Northern Ireland, this situation is dire and time-sensitive, with bureaucratic hurdles inhibiting men from receiving the essential treatment. Despite not serving as a cure, abiraterone has proven effective in preventing the spread of prostate cancer to other parts of the body. In Wales and Scotland, even patients whose cancer has not spread are eligible for the drug. Research indicates that the drug significantly boosts the survival rate for earlier-stage patients, with a notable reduction in the progression of the cancer.
Recent findings from a trial named Stampede, which was published in 2022, have emphasized the potential impact of abiraterone on extending lives. The trial highlighted improved survival rates for patients treated with abiraterone alongside standard care, leading to the recommendation that it should be considered a new standard treatment. Giles Turner, a retiree from Sussex, chose to pay for the drug privately after being diagnosed with prostate cancer in 2023, as NHS England was yet to approve its use for a wider group of men. Despite his good fortune in being able to afford treatment, Turner lamented the injustice faced by others who couldn’t access the drug.
As the debate surrounding the approval of abiraterone in England continues, many are left wondering why NHS England has not aligned its policies with those of NHS Scotland and NHS Wales. Turner, who has spent £20,000 on treatment so far, criticized the system’s preference for funding expensive patented drugs while overlooking the affordability of abiraterone, which costs the NHS a mere £77 per pack per month. The lack of progress in making the drug more widely available underscores the urgent need for a comprehensive review of funding priorities within the healthcare system
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found. Blocked by captcha.